Latest news with #PASG
Yahoo
2 days ago
- Business
- Yahoo
Wall Street Analysts Believe Passage Bio (PASG) Could Rally 1415.15%: Here's is How to Trade
Shares of Passage Bio, Inc. (PASG) have gained 31.5% over the past four weeks to close the last trading session at $7.59, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $115 indicates a potential upside of 1415.2%. The mean estimate comprises four short-term price targets with a standard deviation of $103.76. While the lowest estimate of $40.00 indicates a 427% increase from the current price level, the most optimistic analyst expects the stock to surge 3325.6% to reach $260.00. It's very important to note the standard deviation here, as it helps understand the variability of the estimates. The smaller the standard deviation, the greater the agreement among analysts. While the consensus price target is a much-coveted metric for investors, solely banking on this metric to make an investment decision may not be wise at all. That's because the ability and unbiasedness of analysts in setting price targets have long been questionable. But, for PASG, an impressive average price target is not the only indicator of a potential upside. Strong agreement among analysts about the company's ability to report better earnings than they predicted earlier strengthens this view. While a positive trend in earnings estimate revisions doesn't gauge how much a stock could gain, it has proven to be powerful in predicting an upside. Price, Consensus and EPS Surprise Here's What You Should Know About Analysts' Price Targets According to researchers at several universities across the globe, a price target is one of many pieces of information about a stock that misleads investors far more often than it guides. In fact, empirical research shows that price targets set by several analysts, irrespective of the extent of agreement, rarely indicate where the price of a stock could actually be heading. While Wall Street analysts have deep knowledge of a company's fundamentals and the sensitivity of its business to economic and industry issues, many of them tend to set overly optimistic price targets. Are you wondering why? They usually do that to drum up interest in shares of companies that their firms either have existing business relationships with or are looking to be associated with. In other words, business incentives of firms covering a stock often result in inflated price targets set by analysts. However, a tight clustering of price targets, which is represented by a low standard deviation, indicates that analysts have a high degree of agreement about the direction and magnitude of a stock's price movement. While that doesn't necessarily mean the stock will hit the average price target, it could be a good starting point for further research aimed at identifying the potential fundamental driving forces. That said, while investors should not entirely ignore price targets, making an investment decision solely based on them could lead to disappointing ROI. So, price targets should always be treated with a high degree of skepticism. Here's Why There Could be Plenty of Upside Left in PASG Analysts' growing optimism over the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher, could be a legitimate reason to expect an upside in the stock. That's because empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. The Zacks Consensus Estimate for the current year has increased 8.7% over the past month, as one estimate has gone higher compared to no negative revision. Moreover, PASG currently has a Zacks Rank #2 (Buy), which means it is in the top 20% of more than 4,000 stocks that we rank based on four factors related to earnings estimates. Given an impressive externally-audited track record, this is a more conclusive indication of the stock's potential upside in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> . Therefore, while the consensus price target may not be a reliable indicator of how much PASG could gain, the direction of price movement it implies does appear to be a good guide. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Passage Bio, Inc. (PASG) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Business Insider
12-07-2025
- Business
- Business Insider
Passage Bio trading halted, news pending
19:50 EDT Passage Bio (PASG) trading halted, news pending Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Yahoo
10-07-2025
- Business
- Yahoo
Passage Bio Announces 1-for-20 Reverse Stock Split
PHILADELPHIA, July 10, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. ('Passage Bio' or the 'Company') (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that its Board of Directors ('Board') has approved a reverse stock split of the company's outstanding shares of common stock at a ratio of 1-for-20. The reverse stock split will become effective at 12:01 a.m. Eastern time on July 14, 2025. Passage Bio's common stock will begin trading on a post-reverse stock split basis on July 14, 2025, under the Company's existing trading symbol 'PASG' with a new CUSIP number of 702712 209. The reverse stock split is intended to regain compliance with Nasdaq's minimum bid price requirement of $1.00 per share. The reverse stock split was approved by Passage Bio's stockholders, at the Company's 2025 annual meeting of stockholders held on May 28, 2025, to be effected at the Board's discretion within approved parameters. The reverse stock split reduces the number of shares of the Company's outstanding common stock from approximately 62,405,898 shares to approximately 3,120,295. As a result of the reverse stock split, proportionate adjustments will be made to the exercise prices and number of shares of Passage Bio's common stock underlying the Company's outstanding equity awards for common stock, as well as the number of shares issuable under the Company's equity incentive and inducement plans, and employee stock purchase plan. There will be no change to the number of authorized shares or to the par value per share. Information for Passage Bio's Stockholders Passage Bio's transfer agent, Computershare Trust Company, N.A., will serve as the exchange agent for the reverse stock split. Registered stockholders holding pre-split shares of Passage Bio's common stock electronically in book-entry form are not required to take any action to receive post-split shares. Those stockholders who hold their shares in brokerage accounts or in 'street name' will have their positions automatically adjusted to reflect the reverse stock split, subject to each broker's particular processes, and will not be required to take any action in connection with the reverse stock split. None of Passage Bio's common stock is held in certificate form. No fractional shares will be issued in connection with the reverse stock split. Stockholders who would otherwise be entitled to receive fractional shares will receive the number of shares of common stock as rounded up to the nearest whole share. The reverse stock split will affect all of the Company's stockholders uniformly and would not affect any stockholder's percentage ownership interests, except to the extent that the reverse stock split results in such stockholder owning a fractional share. About Passage Bio, Inc. Passage Bio (Nasdaq: PASG) is a clinical stage genetic medicines company on a mission to improve the lives of patients with neurodegenerative diseases. Our primary focus is the development and advancement of cutting-edge, one-time therapies designed to target the underlying pathology of these conditions. Passage Bio's lead product candidate, PBFT02, seeks to treat neurodegenerative conditions, including frontotemporal dementia, by elevating progranulin levels to restore lysosomal function and slow disease progression. To learn more about Passage Bio and our steadfast commitment to protecting patients and families against loss in neurodegenerative conditions, please visit: Forward Looking Statements This press release contains 'forward-looking statements' within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995, including, but not limited to, Passage Bio's future stock price, the effects of the reverse stock split on stockholders, compliance with Nasdaq listing standards and Passage Bio's ability to remain listed on the Nasdaq Capital Market. These forward-looking statements may be accompanied by such words as 'aim,' 'anticipate,' 'believe,' 'could,' 'estimate,' 'expect,' 'forecast,' 'goal,' 'intend,' 'may,' 'might,' 'plan,' 'potential,' 'possible,' 'will,' 'would,' and other words and terms of similar meaning. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Information about the risks and uncertainties faced by Passage Bio is contained in the section captioned "Risk Factors" in documents the Company files from time to time with the Securities and Exchange Commission ('SEC') and other reports as filed with the SEC. In addition, the Company's forward-looking statements could be affected by general industry and market conditions and regulatory approvals. You are cautioned not to place undue reliance on these forward-looking statements, which are made only as of the date of this press release. Passage Bio undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise or revise these forward-looking statements to reflect new events, uncertainties or other contingencies. Investor Contact:Stuart HendersonPassage Bioshenderson@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
15-05-2025
- Business
- Business Insider
Chardan Capital Reaffirms Their Buy Rating on Passage Bio (PASG)
In a report released yesterday, Geulah Livshits from Chardan Capital maintained a Buy rating on Passage Bio (PASG – Research Report), with a price target of $6.00. The company's shares closed yesterday at $0.27. Confident Investing Starts Here: Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter According to TipRanks, Livshits is a 5-star analyst with an average return of 16.2% and a 37.68% success rate. Livshits covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics, Solid Biosciences, and Passage Bio. Passage Bio has an analyst consensus of Strong Buy, with a price target consensus of $7.33. Based on Passage Bio's latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $15.41 million. In comparison, last year the company had a GAAP net loss of $16.71 million Based on the recent corporate insider activity of 12 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of PASG in relation to earlier this year. Last month, Orbimed Advisors Llc, a Major Shareholder at PASG sold 149,054.00 shares for a total of $49,704.12.
